I had my 38 week appointment today and it was a great one! Everything is still looking good (BP, urine, weight, heartbeat, etc.), but I'm still not dilated at all. The doctor felt around and said she's still head-down and feels like she's dropped some. According to fundal height, she was measuring 40 weeks today.
WE SET OUR EVICTION DATE!! The doctor said that he thinks we already have a pretty good sized baby and doesn't want me to go more than another week. He does his inductions on Thursdays. So, depending on how my cervix and everything looks at our appointment on Monday, we will either go in Wednesday night to prep my cervix or Thursday morning to start pitocin. YAY!
Re: Great appointment today! Another eviction date set...
Looks like we are on the same schedule
I can't remember what he called it, but he said they would prep my cervix and monitor me in the hospital overnight, then start pitocin the next morning. I asked him if it was what people commonly referred to as "stripping membranes" and he said no. lol. WOOHOO for an eviction date!!
Then came a miscarriage March '11
Then came a baby in the baby carriage May 16, 12
Waiting on our second little peanut!
Prostaglandin is not the name of a drug, but a class of drugs. He will probably either use cytotec (misoprostol) or cervadil (dinoprostone). They help ripen your cervix and then they might use pitocin.
Prostaglandins
Recommendations for pharmacological induction of labor with prostaglandins differ. ACOG states that both PGE analogues (misoprostol and dinoprostone) are effective for cervical ripening and induction of labor. According to ACOG, there is extensive clinical experience with misoprostol and a large body of published reports supporting its safety and efficacy when used appropriately. No studies, ACOG continues, indicate that intrapartum exposure to misoprostol has any long-term adverse health consequences to the fetus in the absence of fetal distress, nor is there a plausible biologic basis for such a concern. They add that the FDA in 2002 approved a new label on the use of misoprostol during pregnancy for cervical ripening and for the induction of labor. This labeling does not contain claims regarding the efficacy or safety of misoprostol, nor does it stipulate doses or dose intervals.
NICE, in contrast to ACOG, states that vaginal PGE2 (dinoprostone) is the preferred method of induction of labor, unless there are specific clinical reasons for not using it (in particular the risk of uterine hyperstimulation). Moreover, according to NICE, misoprostol should only be offered as a method of induction of labor to women who have intrauterine fetal death or in the context of a clinical trial. Misoprostol is not licensed for use in pregnancy in the UK. In the full version of its guidance, NICE states that a review conducted by the World Health Organization (in press at the time of publication of the guideline) of the evidence from four systematic reviews concluded that the currently available studies are not large enough to have adequate statistical power to assess the safety issues of the induction process with misoprostol and the long-term follow up of babies exposed to misoprostol. Trials or metaanalyses that have adequate power to address rare adverse fetal outcomes will need to include in excess of 30,000 women, according to NICE.
An additional difference lies in recommendations concerning appropriate methods of administration of dinoprostone. ACOG cites intracervical administration (in addition to vaginal administration) as an appropriate method, while NICE recommends only vaginal administration and recommends against oral, intravenous, extra-amniotic, and intracervical PGE2administration. In the full version of its guidance, NICE states that for women with an unfavorable cervix, intracervical PGE2 is less effective than vaginal PGE2 and confers no benefit. For women with a favorable cervix, it achieves similar maternal outcomes as vaginal PGE2, but is invasive. They add that intracervical PGE2 is not commonly used in the UK.
https://guideline.gov/syntheses/synthesis.aspx?id=24079